• No se han encontrado resultados

A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting

N/A
N/A
Protected

Academic year: 2020

Share "A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting"

Copied!
10
0
0

Texto completo

Loading

Figure

Figure 1 Experimental model of Winn assay.
Figure 3 Evolution of M-406 tumor growth with inoculum by trocar in the three lines of mice
Figure 4 Escape and elimination phases in CBi, CBi − and CBi/L mice. a) Tumor volume doubling time (TvDT); CBi vs CBi/L (P = 0.0014, Mann Whitney test); b) Survival curves of CBi and CBi/L mice in ES phase (P < 0.0001, Log-rank test Mantel-Cox); c) Maxi
Figure 5 Lung metastasis development in CBi (n = 52) and CBi/L (n = 50) mice. a) Percentage of mice developing metastasis
+3

Referencias

Documento similar

Moreover, a recent report has shown that p38α may sensitize cells to apoptosis by phosphorylating epidermal growth factor receptor (EGFR) and inducing its

Serum levels of vascular endothelial growth factor-A 165 , soluble vascular endothelial growth factor receptor 1, and hepatocyte growth factor were assessed by

Overall, this study shows that the activation of ERK5 MAPK by model Gq-coupled GPCRs does not depend on receptor internalization, β-arrestin recruitment or

Real Academia Nacional de Medicina, 2012, https://dtme.ran m.es/buscador.a spx?NIVEL_BU S=3&LEMA_B US=receptor%2 0AMPA [último acceso en septiembre de 2018].. Receptor

(2015) Human Epidermal Growth Factor Receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the Immunotherapy of HER2- positive sarcoma.. Journal of

(Helsinki). How cells respond to interferons. Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor. The expression of the Hodgkin's

Abbreviations: ACE, angiotensin converting enzyme; Ang II, angiotensin II, ARB, angiotensin receptor blockers; ARE, antioxidant responsive element; AT1R, angiotensin II receptor type

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: results of a phase I